More serious but rare adverse events include pancreatitis, gallbladder disease, and thyroid C-cell tumours (patients should be advised to report symptoms such as neck mass, dysphagia or persistent hoarseness)
GLP-1s have also been studied as a possible treatment medication for AUD
Listed effects of GLP-1 include: 1) reduced glucagon secretion from the liver (thereby slowing down the release of glucose, or blood sugar, into the bloodstream during periods of fasting or reduced food intake), 2) increased insulin production, 3) decreased appetite, and 4) decreased intestinal motility (causing food to move slower through the digestive system, thereby further improving blood sugar and reducing appetite)
A small percentage of patients may find that Semaglutide produces only a mild reduction in appetite, even after reaching the highest therapeutic doses
It raises an important questioncan GLP-1 medications cause irritability or anger